The global cell and gene therapy clinical trials market size is estimated to reach USD 39.41 billion by 2033, registering to grow at a CAGR of 15.58% from 2025 to 2033, according to a new report by Grand View Research, Inc. Cell and gene therapy (CGTs) signify the next great movement of therapeutic innovation and have resulted in the development of promising therapies around the world. Although a few of the early therapies have got marketing approval in the U.S., there are numerous promising therapies in development across the world. During the pandemic, the majority of clinical studies were focused on COVID-19. However, owing to the decline in COVID-19 cases, the market players are now shifting their focus to the development of CGTs.
For instance, in February 2022, the life sciences company, Cytiva, collaborated with NecstGen to develop gene therapies. Such collaborations are likely to promote market growth post-pandemic. The market has witnessed significant growth over the past few years, with a rise in the CGT pipeline. As reported by Global Data, in March 2021, over 2,400 CGT drugs were in the pipeline, whereas in 2020 there were over 551 CGT drugs in the clinical phase. In addition, investment is rolling into companies of various types, ranging from startups to major acquisitions by significant biopharmaceutical companies. In 2019, 19 deals of M&A worth over USD 156 billion were completed.
The largest of these was the acquisition of Celgene and its pipeline of numerous cell therapy assets for oncology treatment by Bristol-Myers Squibb for USD 74 billion. Such deals are likely to improve the market growth as CGT is gaining popularity in the treatment of life-threatening diseases. Research funding in CGT has improved in the post-pandemic period. For instance, in January 2022, researchers at the University of York received a grant of USD 3.1 million to support stem cell gene therapy research to treat sickle cell disease. In March 2022, researchers at the Indiana University School received funding of USD 12 million to develop safe gene therapy for treating hemophilia. Such investments are likely to have a positive impact on market growth.
Request a free sample copy or view the report summary: Cell And Gene Therapy Clinical Trials Market Report
The phase II segment accounted for the largest share in 2024 owing to a large number of therapies currently in development in phase II.
The oncology indication segment accounted for the largest share in 2024 as a high number of CGT trials are focused on the treatment of cancer.
North America dominated the global market in 2024. This is largely attributed to a large number of clinical trial activities in the U.S. and favorable government support.
Asia Pacific is expected to register the fastest CAGR over the forecast period owing to the increasing number of biotechnology companies focusing on CGTs.
Grand View Research has segmented the global cell and gene therapy clinical trials market based on phase, indication, and region:
Cell And Gene Therapy Clinical Trials Phase Outlook (Revenue, USD Million, 2021 - 2033)
Phase I
Phase II
Phase III
Phase IV
Cell And Gene Therapy Clinical Trials Indication Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Cardiology
CNS
Musculoskeletal
Infectious diseases
Dermatology
Endocrine, metabolic, genetic
Immunology & inflammation
Ophthalmology
Hematology
Gastroenterology
Others
Cell And Gene Therapy Clinical Trials Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Norway
Sweden
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Cell And Gene Therapy Clinical Trials Market
IQVIA
ICON Plc
LabCorp
Charles River Laboratories
PAREXEL International Corp.
Syneos Health
Medpace
Thermo Fisher Scientific, Inc.
Novotech
Veristat, LLC
"The quality of research they have done for us has been excellent..."